Abstracts tagged "ANCA and cardiovascular disease"

Abstract Number: 2631 • 2019 ACR/ARP Annual Meeting
Increased Risk of Acute Coronary Artery Disease and Ischemic Stroke in Patients with Eosinophilic Granulomatosis with Polyangiitis
Morgane Mourguet ¹, Dominique Chauveau ², Stan Faguer ², JB Ruidavets ², Yannick Béjot ³, Grégoire Prevot ⁴, Olivier Lairez ², David Ribes ², Antoine Huart ², Laurent Alric ², Leo Astudillo ¹, Laurent Sailler ¹ and Grégory Pugnet⁵, ¹CHU Purpan, Toulouse, France, ²CHU Rangueil, Toulouse, France, ³CHU Dijon, Dijon, France, ⁴CHU Larrey, Toulouse, France, ⁵CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France
Background/Purpose: Current treatment approaches have greatly improved the survival of eosinophilic granulomatosis with Polyangiitis (EGPA) patients, however both morbidity andmortality are still significant mainly due…
Abstract Number: 752 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Outcomes Are Worse In Microscopic Polyangiitis Compared To Granulomatosis With Polyangiitis: Data From An Inception Cohort Of Patients With Anti-Neutrophil Cytoplasm Antibody Associated Systemic Vasculitis
Anna Mistry¹, Joanna Robson², Susan L Hogan³, Caroline Poulton³, Yichun Hu⁴, Ronald Falk⁵ and Raashid A. Luqmani⁶, ¹Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³UNC Kidney Center, Chapel Hill, NC, ⁴UNC Kidney Centre, University of North Carolina, Chapel Hill, North Carolina, Chapel Hill, NC, ⁵Dept of Nephrology and Hypertension, UNC Kidney Center, Chapel Hill, NC, ⁶Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom
Background/Purpose: A greater than three-fold increase in cardiovascular mortality as been reported within the first five years of diagnosis of anti-neutrophil cytoplasmic antibody (ANCA) associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].